Absolute Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Absolute Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.98M	Sell	25,210 -819	-3%	-$129K	0.92%	33
2026 Q2	$4.12M	Buy	26,029 +6,345	+32%	+$858K	1.03%	32
2026 Q1	$2.51M	Buy	19,684 +45	+0.2%	+$5.62K	0.84%	39
2025 Q4	$2.39M	Buy	19,639 +7,339	+60%	+$841K	0.87%	39
2025 Q3	$1.23M	Buy	+12,300	New	+$1.11M	0.53%	60
2022 Q4	–	Sell	-26	Closed	-$2.05K	–	517
2022 Q3	$2.05K	Buy	+26	New	+$2.19K	﹤0.01%	310

Other funds holding XBI

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Natixis Paris, France $28B AUM 27.03% 1-Year Est. Return

Investure LLC Charlottesville, Virginia $1.83B AUM 14.32% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return

Absolute Capital Management's XBI Position: Q3 2026 in Review

Absolute Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 3.1% in Q3 2026, selling an estimated $129K and leaving 25,210 shares worth $3.98M. The position accounts for 0.92% of the portfolio, ranked #33.

Absolute Capital Management first reported a position in XBI in Q3 2022 and has held it in 6 quarters since. The position peaked at $4.12M in Q2 2026. 545 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Absolute Capital Management held 25,210 shares of State Street SPDR S&P Biotech ETF worth $3.98M as of Q3 2026.
Absolute Capital Management sold 819 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $129K.
State Street SPDR S&P Biotech ETF made up 0.92% of Absolute Capital Management's portfolio in Q3 2026, its #33 holding.
Absolute Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2022 and has held it in 6 quarters since.
Absolute Capital Management's State Street SPDR S&P Biotech ETF position peaked at $4.12M in Q2 2026.
545 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Absolute Capital Management's 13F filing for Q3 2026, filed 16 Oct 2026.